estradiol
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Turner Syndrome
Conditions
Turner Syndrome
Trial Timeline
Jun 1, 2005 → Mar 1, 2013
NCT ID
NCT00134745About estradiol
estradiol is a approved stage product being developed by Novo Nordisk for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00134745. Target conditions include Turner Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00134745 | Approved | Completed |
Competing Products
10 competing products in Turner Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| somatotropin | Pfizer | Pre-clinical | 22 |
| Lonapegsomatropin + Somatropin | Ascendis Pharma | Phase 2 | 49 |
| Somatropin (rDNA origin) | Ipsen | Phase 3 | 74 |